Roivant Sciences Director Sells $203K Under 10b5-1 Plan
Roivant Sciences Ltd.
Subscribe to track ROIV
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Roivant Sciences Ltd. (ROIV) - Form 4 Insider Filing
**Insider:** Meghan Fitzgerald
**Role:** Director
**Transaction Date:** 2026-09-15
**Filing Date:** 2026-09-17
### Transaction Summary
- **Type:** Open Market Sale (Rule 10b5-1)
- **Shares Sold:** 5,112
- **Average Price:** ~$39.74 ($39.68 - $40.45)
- **Total Consideration:** $203,152.16
- **Post-Transaction Holdings:** 36,108 shares (Direct)
### Significance
- **Low**: Executed pursuant to a Rule 10b5-1 trading plan adopted on March 30, 2026, representing routine diversification.
Comprehensive Analysis
Executive Summary
On September 17, 2026, Roivant Sciences Ltd. (NASDAQ: ROIV) filed a Form 4 detailing insider sales by Director Meghan Fitzgerald. On September 15, 2026, Director Fitzgerald sold a total of 5,112 Common Shares across two transactions at weighted average prices of $39.68 and $40.45, generating total gross proceeds of approximately $203,152.16.
Transaction Breakdown
- Transaction 1: Sold 4,712 shares at a weighted average price of $39.68 (range: $39.26 to $40.25).
- Transaction 2: Sold 400 shares at a weighted average price of $40.45 (range: $40.28 to $40.51).
- Remaining Holdings: 36,108 Common Shares held directly.
Context and Analysis
Both transactions were executed under a pre-established Rule 10b5-1 trading plan adopted on March 30, 2026. The adoption occurred more than five months before execution, comfortably meeting standard cooling-off requirements. The disposition represents approximately 12.4% of the insider's direct equity position prior to the sales, leaving a substantial remaining stake of 36,108 shares. Given the programmatic nature and modest aggregate value, this transaction is considered low significance.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.